Search Medical Condition
Please enter condition
Please choose location from dropdown

Zrifin, Israel Clinical Trials

A listing of Zrifin, Israel clinical trials actively recruiting patients volunteers.

RESULTS

Found (871) clinical trials

Non-Polymer-Based Rapamycin-Eluting Stents to Prevent Restenosis

In-stent restenosis remains the major problem limiting the efficacy of coronary stenting. Either sirolimus or paclitaxel drug-eluting stents have been demonstrated to decrease neointima proliferation resulting in a remarkable reduction of restenosis rate. However, despite the outstanding results achieved with this novel approach to restenosis, some caveats still remain. Although ...

Phase

0.0 miles

Learn More »

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed prior 12-week induction study AMAN (NCT03518086).

Phase

0.0 miles

Learn More »

Capsulized Fecal Microbiota Transplantation in Pediatric Ulcerative Colitis Patients

Fecal Microbiota Transplantation(FMT) - reconstitution of normal flora by a stool transplant from a healthy individual, is increasingly being recognized as a therapeutic modality for diseases that are associated with gut dysbiosis. This is a placebo-controlled, double blinded interventional study evaluating multiple, oral, fecal microbiota transplantation, administered in newly diagnosed ...

Phase

0.0 miles

Learn More »

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

This study designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC).

Phase

0.0 miles

Learn More »

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.

Phase

0.0 miles

Learn More »

Fecal Microbiota Transplantation in Ulcerative Colitis

Fecal Microbiota Transplantation(FMT) - reconstitution of normal flora by a stool transplant from a healthy individual, is increasingly being recognized as a therapeutic modality for diseases that are associated with gut dysbiosis. This is a placebo-controlled, double blinded interventional study evaluating multiple, oral, fecal microbiota transplantation, administered in newly diagnosed ...

Phase

0.0 miles

Learn More »

Safety Tolerability and Efficacy of Rapid Optimization Helped by NT-proBNP and GDF-15 of Heart Failure Therapies

STRONG-HF is a multicenter, randomized, parallel group study designed to evaluate the efficacy and safety of up-titration of standard of care medical therapy including beta-blockers; angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blocker (ARB) or angiotensin receptor neprolysin inhibitor (ARNi); and mineralocorticoid receptor antagonist (MRAs), on morbidity and mortality when ...

Phase N/A

0.0 miles

Learn More »

Association Between Soy Based Formula in Infancy and Puberty

Soy and soy-based products are widely used in modern day nutrition. It is widely consumed among all populations, especially among vegetarians, vegans, those with milk allergy, and in the general population who consume processed foods .Soy-based infant formula is commonly used, and may account for nearly 25 % of the ...

Phase N/A

0.0 miles

Learn More »

Impact of Exposure to Environmental Pollutants on Birth Outcomes in an Israeli Cohort

Objectives and hypothesis The scale and diversity of chemicals in worldwide use today is vast, ranging from pharmaceuticals and food products, to plastics, gasoline, and semiconductor chips. Many of these chemicals are released into the environment where they are found in air, water, soil, in house dust, and in the ...

Phase N/A

0.0 miles

Learn More »

CYP2D6 Genotyping by AmpliChipTM CYP450 for Tamoxifen-Treated Breast Cancer Patients

Tamoxifen, the first-line drug for preventing breast cancer relapse, is typically prescribed for a 5-year follow-up period after diagnosis and primary treatment of estrogen receptor-positive breast cancer. Recent studies show that tamoxifen is only a pro-drug, while its major active metabolite, endoxifen, is formed in vitro by the liver enzyme ...

Phase N/A

0.0 miles

Learn More »